Core Viewpoint - Inspire Medical Systems, Inc. is facing a federal securities class action due to allegations of misleading statements regarding the launch and demand for its Inspire V device, with a deadline for investors to seek lead plaintiff status set for January 5, 2026 [1][3]. Group 1: Allegations and Legal Action - The complaint claims that Inspire Medical and its executives violated federal securities laws by making false or misleading statements about the market demand for the Inspire V device and the company's readiness for its launch [3]. - The law firm Faruqi & Faruqi is investigating potential claims against Inspire Medical and encourages anyone with relevant information to come forward [7]. Group 2: Launch Issues and Financial Impact - On August 4, 2025, Inspire Medical announced significant delays in the launch of the Inspire V device, citing incomplete training and onboarding at treatment centers as major factors [4]. - The company also faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025, preventing implanting centers from billing for procedures [4]. - Inspire reported weak demand and excess inventory for the Inspire V, leading to a drastic cut in its 2025 earnings guidance by over 80% [5]. - Following these announcements, Inspire's stock price plummeted by more than 32%, from $129.95 per share to $87.91 per share, resulting in a loss of approximately $1.2 billion in market capitalization [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged misleading statements regarding the launch of its Inspire V product, which reportedly faced significant challenges and poor demand [2][7]. Allegation Details - The lawsuit claims that during the class period, Inspire Medical made false statements about the successful launch of Inspire V, while in reality, the launch was hindered by poor demand and excess inventory at provider centers [7]. - It is alleged that many centers did not complete necessary training and onboarding before the product's launch, which contributed to the poor rollout [7]. - The company admitted that software updates for billing procedures were delayed, impacting the ability of implanting centers to process claims [7]. Financial Impact - Following the revelation of these issues on August 4, 2025, Inspire Medical reduced its 2025 earnings guidance by over 80%, leading to a more than 32% decline in the company's stock price [7].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota and targets investors who purchased INSP securities between August 6, 2024, and August 4, 2025 [2][3]. - The Lead Plaintiff Deadline is set for January 5, 2026, urging affected investors to contact legal representatives [3]. Allegations of Misleading Information - Inspire Medical allegedly assured investors of its "operational readiness" for the Inspire V launch, claiming it was ready for a full commercial rollout, which the lawsuit argues concealed significant operational failures [3][4]. - The undisclosed operational issues included: - **Medicare & Billing Readiness**: Necessary software updates for Medicare claims processing were not effective until July 1, 2025, preventing implanting centers from billing for procedures, which stalled early adoption and revenue generation [4]. - **Excess Inventory**: A significant surplus of the older Inspire IV device impacted demand for the new Inspire V, leading to a need for inventory reduction [4]. - **Training & Onboarding**: Many treatment centers had not completed essential training for the new device, contributing to operational delays [4]. Impact on Business and Stock - The alleged operational failures resulted in a drastic cut to Inspire's 2025 earnings per share (EPS) guidance by over 80%, leading to a stock price drop of $42.04 per share, equating to a 32.4% decline in value [4]. Investigation Focus - Hagens Berman's investigation emphasizes the concealment of critical issues, particularly the Medicare claims software failure and the inventory glut of the prior device, suggesting that management prioritized a narrative of seamless transition over operational reality [5]. Legal Options for Investors - Investors who purchased INSP securities during the class period may have legal options and are encouraged to contact Hagens Berman for further information [5].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][4]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, preventing implanting centers from billing for procedures [4]. - An excess inventory of the older Inspire IV device created a channel glut, negatively impacting demand for the new Inspire V product and necessitating an inventory "burn down" [4]. - Many treatment centers had not completed essential training for the new device, contributing to the launch's failure [4]. - As a result of these issues, Inspire Medical slashed its 2025 EPS guidance by over 80%, leading to a $42.04 per share drop and a 32.4% decline in stock value [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman to discuss their legal rights before the January 5, 2026, Lead Plaintiff Deadline [2][3]. - Hagens Berman is focusing on the alleged concealment of critical operational failures and is inviting investors to share information that may assist in the investigation [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing legal scrutiny due to allegations of misleading statements regarding the launch and demand for its new Inspire V device, leading to significant financial losses for investors [4][6]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical and has set a deadline of January 5, 2026, for investors to seek the role of lead plaintiff in a federal securities class action [2]. - The firm encourages investors who suffered losses in Inspire Medical to contact them directly to discuss their legal options [1]. Group 2: Financial Impact - On August 4, 2025, Inspire Medical announced delays in the launch of the Inspire V device due to incomplete training and onboarding at treatment centers, as well as billing and reimbursement challenges [5]. - Following the announcement of these setbacks, Inspire Medical's stock price plummeted over 32%, from $129.95 per share to $87.91 per share, resulting in a loss of approximately $1.2 billion in market capitalization [6]. - The company also reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [6]. Group 3: Allegations of Misconduct - The complaint against Inspire Medical alleges that the company and its executives made false and misleading statements about the market demand for the Inspire V device and the steps taken for its successful launch [4]. - Investors were led to believe that demand for the Inspire V was strong, which was contradicted by the subsequent revelations of logistical and demand issues [4]. Group 4: Call for Information - Faruqi & Faruqi, LLP is also seeking information from whistleblowers, former employees, and shareholders regarding Inspire Medical's conduct [8].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to customers having excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025, following this announcement [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 5, 2026 [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the firm or visiting their website [3][6]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors regarding operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [2][3]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, preventing implanting centers from billing for procedures [3]. - An excess inventory of the older Inspire IV device created a channel glut, negatively impacting demand for the new Inspire V product and leading to a significant reduction in 2025 earnings per share (EPS) guidance by over 80% [3]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [3]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the January 5, 2026, Lead Plaintiff Deadline to discuss their legal rights [2][4]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that the stock collapse was due to management prioritizing a narrative over operational reality [4].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations Against Inspire - The complaint alleges that Inspire misled investors by claiming it had taken necessary steps for the launch of Inspire V, while in reality, it failed to prepare clinicians and payors, leading to delays in adoption [5][6]. - The company faced weak demand for Inspire V due to customers having excess inventory of older devices [6]. Group 4: Stock Price Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Inspire Medical and its executives assured investors of the company's "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][4]. - The class period for the lawsuit includes investors who purchased INSP securities between August 6, 2024, and August 4, 2025 [2]. - The lead plaintiff deadline for the lawsuit is January 5, 2026, urging affected investors to contact the law firm Hagens Berman [3]. Group 2: Allegations of Concealment - Allegations include failures in Medicare claims processing software that delayed the rollout of the Inspire V device, impacting revenue generation [4]. - An excess inventory of the older Inspire IV device created a demand issue for the new Inspire V, leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [4]. Group 3: Investigation Focus - Hagens Berman's investigation emphasizes the concealment of critical operational issues, particularly the Medicare claims software failure and the inventory surplus of the Inspire IV device [5]. - The firm asserts that the stock collapse was due to management prioritizing a narrative of a seamless transition over the actual operational challenges [5].